Historische Zeitleiste
Vom alten Ägypten zur modernen Genomik
Zuletzt aktualisiert: June 18, 2026
Der medizinische Blutegel has eine der longest histories in medicine — spanning over three millennia from Egyptian tomb paintings to 21st-century proteomics. This timeline traces der/die wichtigste milestones in the science, regulation, and klinischer Einsatz of Hirudo medicinalis and its bioaktive Verbindungs.
Antike & klassische Periode
Egyptian tomb paintings (18th Dynasty) depict Blutegeltherapie — among the earliest visual evidence of medizinischer Blutegel use in human history.
Nicander of Colophon describes medizinischer Blutegel use in Greek texts, providing eine der earliest written accounts of therapeutic Blutegelanwendung.
Galen endorses bloodletting including leeches as part of humoral medicine. His influence will shape medical practice in Europe and the Islamic world for over a thousand years.
Al-Zahrawi (Albucasis) details surgical Blutegelanwendungs in his surgical encyclopedia. Avicenna includes leeches in the Canon of Medicine, systematizing their use for the medieval Islamic medical tradition.
Der Blutegel-Boom (1800er)
Peak of medical Blutegelnutzung in Europe. Leech therapy becomes der dominante form of bloodletting, eclipsing lancets and scarification.
Broussais champions aggressive Blutegeltherapie in France. France consumes up to 100 million leeches pro Jahr. Russia exports 70 million leeches annually. Prices spike and Wildpopulationen crash.
John Berry Haycraft discovers Antikoagulans activity of Blutegelextrakt — die erste identification of what will later be named hirudin.
Wissenschaftliche Grundlagen (1900er)
Franz isolates the hirudin compound, establishing it as a distinct Antikoagulans Protein produced by der Blutegel Speicheldrüsen.
Professor Shchegolev develops artificial leech breeding techniques. The first leech biofactory is established near Moscow.
Medpiyavka (Medical Leech) association established in Moscow for centralized leech breeding and distribution. Operated until 1956.
Fritz Markwardt achieves die erste purification of hirudin, enabling structural characterization.
I.P. Baskova begins systematic SDS characterization. Her team discovers destabilase, eglins, bdellins, and calin.
Rekombinant hirudin produced for die erste time. Roy Sawyer publishes Leech Biology and Behaviour and founds Biopharm in Swansea, Wales.
Moderne Ära
Microsurgery renaissance: leeches return to the OR for flap and digit salvage.
Die Assoziation der Hirudologen Russlands und der GUS wurde gegründet, mit I. P. Baskova als erster Präsidentin.
Piyavit in Russland zur Thromboseprophylaxe zugelassen.
Lepirudin (Refludan) receives FDA-Zulassung for HIT. Validates der Blutegel-to-drug pipeline.
Bivalirudin (Angiomax) FDA-zugelassenen for PCI anticoagulation.
Desirudin (Iprivask) FDA-zugelassenen for DVT prophylaxis. Michalsen publishes first RCT for Blutegeltherapie in knee OA.
FDA 510(k) clearance for medizinische Blutegel (K040187, Ricarimpex SAS) — zweites Lebewesen mit FDA-Zulassung als Medizinprodukt, nach medizinischen Maden (Lucilia sericata).
Dabigatran (Pradaxa) FDA-zugelassenen — first oral direkter Thrombin-Inhibitor, derived from hirudin SAR research.
Lepirudin freiwillig zurückgezogen. AHTA in den USA gegründet.
Draft Genom assemblies published. 15 anticoagulation factors and 17 antihemostatic Proteine identified.
Destabilase crystal structure solved at 1.1 Å resolution.
Die FDA überträgt die regulatorische Zuständigkeit für Blutegel von CDRH auf CBER.
ASH founded. 440+ bioaktive Proteine im Blutegel-SDS identifiziert; 107 im ASH-Compound-Registry katalogisiert (Lukas/Liu 2018 Sialotranskriptom; 2025-Erweiterung inkl. Theromin, Hirudonin, Saratin-3, Gelin, Leech-Macin).
Was kommt als Nächstes
Future Directions
- Structure-based drug design: The destabilase crystal structure enables computational screening for neuartig thrombolytic agents.
- Rekombinant leech Proteine: Advances in recombinant expression systems are making it feasible to produce individual leech salivary Proteine at pharmaceutical scale.
- Expanded klinische Studien: Growing interest in rigorous RCTs for off-label indications, including OA, chronic pain, and PVD.
- Genomics-driven discovery: With 440+ Protein sequences and full Genom assemblies available, bioinformatics and AI-driven pipelines are identifying neuartig bioaktive Verbindungs — as demonstrated by five major discoveries in 2025.
Verwandte Ressourcen
Blutegel-Biologie-Hub
Overview of <em>Hirudo medicinalis</em> biology.
SDS-Zusammensetzung
Komponenten des Speicheldrüsensekrets.
Pharmakologie-Hub
Arzneimittel aus der Blutegel-Forschung.
Research Roadmap
What comes after 107 catalogued compounds — open questions and 2025-2026 priorities.
Compound Coverage Map
Live taxonomy of all leech-derived bioactive compounds with evidence tiers.